This page shows the latest Moderna Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Could be the largest IPO for a biotech start-up. Moderna Therapeutics, a specialist in messenger RNA-based drugs, has filed a $500m initial public offering (IPO) that would break all ... Moderna’s mRNA technology attempts to turn a patient’s own
A rapid round up of pharma, biotech and healthcare news. Merck and Moderna expand cancer vaccines work. ... Today brings the latest confirmation of that, with Merck &Co expanding its existing collaboration with Moderna Therapeutics to develop and
The company will work with PsiOxus Therapeutics to evaluate the safety and efficacy of the Oxford, UK biotech's enadenotucirev in combination with Opdivo for the treatment of a range of ... Like BMS, Merck &Co has also moved to extend the reach of its
The deal with Moderna Therapeutics will see it use the Cambridge, Massachusetts-based company's novel messenger RNA (mRNA)-based vaccine technology. ... Moderna's mRNA vaccine technology uses the unique mutations present in a patient's tumour to provoke
Shire. Eukarys. monogenic liver diseases; Wilson disease. Moderna Therapeutics. cancer; cardiovascular disease; infectious disease; metabolism. ... Valera LLC (Moderna Therapeutics). Infectious diseases. Merck &Co; Pasteur Institute. No clinical
Research will take place at Alderley Park site
More from news
Approximately 2 fully matching, plus 11 partially matching documents found.
Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... Moderna Therapeutics has received $8m of the grant to fund early-stage trials of the vaccine and plans to submit an investigational new drug
Back to the immuno-oncology theme, near the end of June Merck &Co signed a collaboration agreement with Moderna Therapeutics to use Moderna's mRNA technology to develop personalised cancer vaccines. ... licence. 230. Moderna Therapeutics/ Merck &Co.
Whilst considering nucleic acid-based approaches, it was interesting to see that mRNA company Moderna Therapeutics, which has a number of deals under its belt with AstraZeneca, Alexion and Merck &Co, ... This is Moderna's fourth venture in what it calls
300. Merck/Alnylam. Divestment. Sale of Merck's RNAi therapeutics unit Sirna. 290. ... 144. Moderna Therapeutics/ Alexion Pharmaceuticals. Exclusive discovery and development. Messenger RNA (mRNA) therapeutics in rare diseases for 10 product options.
Commercialisation. Oralair, grass allergy sublingual tablet (pre-registration). 120. Osiris Therapeutics / Mesoblast . ... Moderna Therapeutics / DARPA. R&D grant. mRNA therapeutics for biodefence targets (discovery).
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Oxford, UK-based Evox Therapeutics has appointed its new chief executive officer in the form of Tony de Fougerolles. ... Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.
Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.
US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee chair. ... Dr Noubar Afeyan, co-founder and chairman of Moderna Therapeutics, said: “We are delighted to welcome Israel to Moderna's
Bringing over 30 years of clinical development experience to the role, he joins from Moderna Therapeutics where he most recently served as president and chief scientific officer.
Former Sanofi Pasteur policy head joins Moderna Therapeutics firm. Valera, one of Moderna Therapeutics' venture companies, has appointed Dr Michael Watson as its new president. ... Moderna's technology, coupled with its goal to deliver transformative
More from appointments
Approximately 3 fully matching, plus 5 partially matching documents found.
Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...